TAmiRNA

Executive Summary

TAmiRNA is an Austrian biotechnology company founded in 2013 that specializes in discovering and developing microRNA and cell-free RNA biomarkers for precision medicine diagnostics. The company focuses on age-associated and complex diseases, offering both diagnostic kits and comprehensive RNA analysis services to researchers and clinicians. By leveraging its proprietary biomarker discovery platform, TAmiRNA aims to enable early detection, patient stratification, and monitoring of diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. With its headquarters in Vienna, the company operates in the rapidly growing liquid biopsy and molecular diagnostics market, positioning itself as a player in non-invasive testing. While TAmiRNA has not disclosed significant funding rounds or commercial partnerships to date, its focus on microRNA—a promising class of biomarkers—could unlock value as the field matures. The company's ability to validate and commercialize its assays will be critical to its success, especially given the competitive landscape dominated by larger diagnostics firms. Overall, TAmiRNA represents an early-stage opportunity in precision diagnostics with potential but requiring further de-risking through clinical validation and market adoption.

Upcoming Catalysts (preview)

• Q3 2026CE Marking of a Novel microRNA Diagnostic Kit60% success
• Q4 2026Strategic Partnership with a Pharmaceutical or Diagnostic Company40% success
• Q1 2027Publication of Clinical Validation Data for Age-Associated Disease Biomarker70% success